^
Association details:
| Biomarker: | BRAF fusion |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
BRAF fusion in lung cancer
Published date:
05/29/2020
Excerpt:
...Nine patients received EGFR-TKI therapy...the median TTD (time to discontinue) of TKIs was 26 months (range 17 to 46). The EGFR mutation still exist when EGFR-TKIs resistance, included EGFR primary mutation, T790M, and C797S, concurrent with BRAF fusion.
DOI:
10.1200/JCO.2020.38.15_suppl.e21598
